HeraBEAT users could be in line for full refunds on the cost of the product
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Medical technology company, HeraMED Limited (ASX:HMD) is pursuing verification around the potential for its HeraBEAT and HeraCARE solutions to be reimbursed under the US reimbursement code system.
Should this occur, under new CPT (Current Procedural Terminology) codes users of HeraMED’s HeraBEAT and HeraCARE solutions would receive a full refund for the cost of the product.
CPT codes are procedural codes used for reporting medical, diagnostic, and surgical services performed by healthcare providers. The American Medical Association (AMA) holds the copyright to CPT codes used nationwide in the US.
Six new codes were recently introduced to help physicians and other healthcare professionals report a range of digital health services, including in home monitoring and electronic patient visits.
This feeds into the global Patient Monitoring Devices Market, which will surpass US$27 billion by 2025, with the North America patient monitoring devices market share anticipated to witness more than 4% growth in forthcoming future.
HeraMED plans to pursue verification around the potential to be reimbursed through these recently introduced CPT codes.
“With the advance of new technologies for e-visits and health monitoring, many patients are realising the best access point for physician care is once again their home,” AMA President Patrice Harris, MD, MA, said in a recent press release.
As part of its US market entry, HeraMED will engage with medical professionals and other expert consultants to verify if its HeraBEAT and HeraCARE platform may be eligible for reimbursement through the current set of CPT codes.
The company will also monitor for the introduction of new codes, which are expected over the course of 2020.
If HeraMED’s solutions are eligible, this may potentially drive uptake with key medical organisations and insurance companies throughout the country.
100% refund to the end user
HeraMED will initially target the following codes, which if its solution use is accepted, will potentially result in a total of US$115 in reimbursement per month, or a full refund to the end user.
● CPT code 99453 - US$19.46 on a one-off basis for the set up and patient education of solutions.
● CPT code 99454 - US$64.15 on a monthly basis for use of remote monitoring services including supply of daily recording and alert transmission.
● CPT code 99547 - US$51.54 (non-facility) and US$32.44 (facility) on a monthly basis for remote treatment monitoring services for 20 minutes or more by a clinical professional or healthcare professional requiring interactive communication with a patient or caregiver.
The CPT code allocation is determined by a dedicated CPT committee and insurance companies and while HeraMED is confident of a positive outcome, timing and path to allocation will be in the hands of third party providers.
The following table indicates the cost of HeraMED’s products and therefore what users could expect to receive back in terms of refund.
Underlining the significance of this development in terms of recognising the growing need for remote patient monitoring, chief executive and co-founder David Groberman said, “These new codes represent the continued trend towards remote patient monitoring and will become imperative as hospitals and health systems look to extend their reach of care to the home and non-traditional settings.
“As healthcare providers look to further increase their collaborations with patients and other care providers, HeraMED becomes better positioned as an innovative technology provider and a potential early mover in digital pregnancy monitoring.
“The company will continue to leverage its partnerships in the USA to progress its market entry and drive solution uptake.”
Board and management will provide further guidance on HeraMED’s US market entry progresses across calendar year 2020.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.